Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nutriman, give it up, it's over. You heard Ray.
The board will discuss the "future" which means
either BK or sellout for pennies.
That's that. Stop posting nonsense.
NUTRIMAN, where are you???
Bernie:
Would you care to guess at the number of NAKED SHORTS that WILL be covered tomorrow?
Genta Incorporated Announces Conference Call to Review Top-Line Results of AGENDA Phase 3 Trial of Genasense® in Patients with Advanced Melanoma
[webcast]
Press Release
Source: Genta Incorporated
On 5:23 pm EDT, Wednesday October 28, 2009
Buzz up! 0 Print
Companies:Genta Incorporated
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETA - News) announced that the Company will host a conference call and live audio webcast to review top-line results of its Phase 3 trial of Genasense® in patients with advanced melanoma. The call will take place on Thursday October 29, 2009 at 8:00 AM ET.
Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.
For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 38149996.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense is being developed as an agent that may enhance the effectiveness of current anticancer therapy. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words “potentially”, “anticipate”, “could”, “calls for”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:
the Company’s ability to obtain necessary regulatory approval for Genasense® from the U.S. Food and Drug Administration (“FDA”);
the safety and efficacy of the Company’s products or product candidates;
the commencement and completion of clinical trials;
the Company’s assessment of its clinical trials;
the Company’s ability to develop, manufacture, license and sell its products or product candidates;
the Company’s ability to enter into and successfully execute license and collaborative agreements, if any;
the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy;
the adequacy of the Company’s patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.
Contact:
PRESS RELEASE!!!!!!!!!!!!!!!!!!!!!!!!!!
If NITE ever files for Bankruptcy, I will dance on their grave.
someone or something is accumulating a lot of shares for the past two days. I have noticed on last sale, some big blocks going through, however, they do not go through consecutively.
Interesting because I haven't seen this recently.
Just a thought.
What do you suppose the "Genasense mechanism action video" will show?
Anyone notice the "investor kit" link on the top right corner on the "new" site?
No trades for 15 min. whats up?
Where did THE_RADMAN GO?
5 50,000 blocks just went through on last sale, but time posted is 20:10:00 (last night 8:10pm). Odd.
that's a "BLOG", an opinion of a pinhead.
Who woke up LTCO on the ASK?
I think you were responding to mine. I should have qualified my statement. The volume looks great compared to the average volume of the last 14 trading days.
Needless to say, the volume is a GREAT sign
Maybe Ray said: "convert all your shares TODAY, because I have news to put out, you evil financiers" lol
HERE WE GO
MM's have capped this at .77 since 12pm EST. They have done this for the past 5 days, with one exception.
If we break one of these caps.......hold on
for a stock with zero uptic potential and toxic financing, you sure are interested in it.
and RBCM is not even logged on the BID side.
THE SME
I gave this some thought tonight and have come to a few loose conclusions:
1. Genta must have recently applied for SME status in order to receive it. EMEA doesn't just hand it out (obvious).
2. Some of the incentives for SME status include a reduction in administrative fees (in some instances up to 90%).
I could not determine the processing time of an SME application, HOWEVER, I believe this tells us that the results are better than positive; they are outstanding.
Why? Well my dear Watson, Genta will be filing EMEA applications in the very near future and seek a reduction in application fees prior to doing so.
A shot across the bow.
Am I stretching it?
DAMN BERNIE,
You nearly gave me a HEART ATTACK!
You aren't the typical person who would yell fire in a crowded theatre.
LOL
This board, along with the YMB has seen some attrition lately. It reminds me of BUD/S. 70% or more will quit.
These are some big buys hitting the ask this last hour.
If ARCA falls off the ask, this thing is gonna run.
whats up with the mm's suddenly stacked up on the bid?
No one accumulates that much money to plop it down on a 50/50 shot. somethings up.
MOVE NORTH NOW!
Hello all;
New here, but old to trading. lol
I came across this about two weeks ago.
I've been doing lots of DD and considering taking
a large position in this.
It appears that the O/S is under 50 million and I also noticed that someone was willing to buy 37 million shares
at 0.08 in the recent S-1.
The S-1 may be the straw that broke the camels back for me.
I may enter into this one.
I have a single question for the board: Does this bad boy have the potential to reach above $1 by mid to late January?
I know I'm asking for speculation, but I have my own opinion and would like to hear others.
Good Luck to All
cbrad; I agree. GETA's products are being clinically tested with other cancers because the hypothesis is that the products work.
big buys hitting the ask now
"You heard"? Does that mean someone actually spoke the words to you? Or did you read it somewhere? Or did you see it on tv?
If you heard it from a person, state his/her name.
If you read it, post the link.
If you saw a video/tv/clip, post it here.
If you have none of the above, then you my friend, are a rumor mill. You simply made it up. But why? Did you get burned? Are you waiting for a lower entry point?
Or are you a bonafide MORON?
are those conversions? or unregistered shares from s1?
115 million shares in a month should give us massive support in the lower end of that range.
If anyone thinks this is retail, they are crazzzzy!
It just STOPPED going down? LOL.
that was over 300,000
SOMETHING IS BREWING. BIG BLOCKS AT 0.836
How dare they draw a salary! Why do they need money? Who do they think they are the CEO & his wife? LOL You guys are funny.
Is this AGENDA or is this another trial using Genasense?
Found it on a website.
http://www.centerwatch.com/clinical-trials/listings/studydetails.aspx?StudyID=156560
Can someone post buys vs sells?
Is there accumulation going on here??